Continuous haemodiafiltration (CVVHDF) is the main form of renal replacement therapy in critically ill patients with severe acute kidney injury. Clotting of the dialysers during CVVHDF is frequent, because most patients with acute kidney injury have an increased risk of bleeding and cannot be systemically anticoagulated. Using data from a randomised controlled trial comparing the efficiency of CVVHDF by placing the dialysis catheter tip at the right atrium or superior vena cava, this study assessed the patient factors associated with an increased risk of frequent clotting of the dialysers-defined by >1 dialysers clotted per day of CVVHDF. Of the 94 patients included in this study, a higher body mass index, a higher platelet count and a lower International Normalized Ratio were associated with an increased risk of frequent clotting of dialysers in the univariate analyses. Use of aspirin or clopidogrel, causes of acute kidney injury and daily dose of nfractionated heparin used were not significantly associated with the risk of frequent clotting of dialysers. In the multivariate parsimony model, only a high body mass index (odds ratio 1.06 per point increment, 95% confidence interval 1.01 to 1.13; P=0.036) and a high platelet count (odds ratio 1.84 per 100x109/l increment, 95% confidence interval 1.17 to 2.91; P=0.009), both in a relatively linear fashion, were independently associated with an increased risk of frequent clotting of dialysers. Optimising the position of the tip of the dialysis catheter may be particularly important for patients with a high body mass index and platelet count in order to reduce frequent clotting of dialysers during CVVHDF.
CITATION STYLE
Ho, K. M., & Morgan, D. J. (2014). Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: A post hoc analysis of a randomised controlled study. Anaesthesia and Intensive Care, 42(1), 59–64. https://doi.org/10.1177/0310057x1404200111
Mendeley helps you to discover research relevant for your work.